| Peter H Kolb, DPT | |
|
901 N Curtis Rd Ste 204, Boise, ID 83706-1340 | |
| (208) 367-3315 | |
| (208) 367-2674 |
| Full Name | Peter H Kolb |
|---|---|
| Gender | Male |
| Speciality | Physical Therapist |
| Location | 901 N Curtis Rd Ste 204, Boise, Idaho |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1003073347 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 225100000X | Physical Therapist | PT2331 (Idaho) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Peter H Kolb, DPT 901 N Curtis Rd Ste 204, Boise, ID 83706-1340 Ph: (208) 367-3315 | Peter H Kolb, DPT 901 N Curtis Rd Ste 204, Boise, ID 83706-1340 Ph: (208) 367-3315 |
News Archive
New legislation forces drug developers to disclose most of their clinical trials data when applying for approval of a new drug. Many will probably think that this is a good idea. However, too much transparency in drug development might be problematic, according to Timo Minssen, researcher at the University of Copenhagen.
This week on Monday (20th April 2020), in a press meet, the World Health Organization (WHO) Director-General said that only around 2 to 3 percent of the global population have antibodies that show they had been infected by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that causes COVID-19 disease.
A new therapy that reduces the risk of mortality and heart failure in patients with mild cardiac disease received a thumb's up this week from an advisory panel to the U.S. Food and Drug Administration. The panel recommended that the cardiac resynchronization therapy defibrillator (CRT-D), tested extensively nationwide under the leadership of cardiologist Arthur Moss, M.D., professor of Medicine at the University of Rochester Medical Center, be approved for use in patients with mild heart failure in the United States.
In a pair of related studies, chemists from the Florida campus of The Scripps Research Institute (TSRI) have identified and designed dozens of molecular "warheads" that not only can detect a key biomarker of cancer, but also could be developed into a potent new class of drug candidates for a range of diseases.
AOAC INTERNATIONAL announced today that it has issued Certificates of Validation for three proprietary test kits that detect SARS-CoV-2, the causative agent of COVID-19 illness, on environmental surfaces.
› Verified 2 days ago
Mrs. Dianne Denise Nelson, PT Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 1130 Allumbaugh St, Boise, ID 83704 Phone: 208-854-8517 | |
Melissa Pirtle, PT Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 703 S Americana Blvd, Suite 130, Boise, ID 83702 Phone: 208-706-7530 Fax: 208-706-7531 | |
Kyle Aaron Holbrook, PT, DPT, NCS Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 600 N Robbins Rd, Boise, ID 83702 Phone: 208-489-4444 | |
Rebecca Wensel, P.T. Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 190 E Bannock St, Boise, ID 83712 Phone: 208-381-2138 | |
Bridget Gilbertson, PT, DPT Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 703 S Americana Blvd Ste 130, Boise, ID 83702 Phone: 208-706-7530 | |
Idaho Physical Therapy Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 1175 E Parkcenter Blvd, Ste 101, Boise, ID 83706 Phone: 208-367-1010 |